Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Immunol Immunother. 2004 Jul;53(7):567-79. Epub 2004 Feb 5.

CD44v6: a target for antibody-based cancer therapy.

Author information

  • 1Boehringer Ingelheim Austria, Dr. Boehringer Gasse 5-11, 1121 Vienna, Austria. Karl-Heinz.Heider@vie.boehringer-ingelheim.com

Abstract

The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural heterogeneity of the gene products is caused primarily by alternative splicing of at least 10 out of 20 exons. Certain CD44 variant isoforms, in particular those containing CD44 variant domain 6 (CD44v6), have been implicated in tumourigenesis, tumour cell invasion and metastasis. Here we will give an overview of immunohistochemically determined CD44v6 expression in human malignancies (primary epithelial and nonepithelial tumours as well as metastases) and normal tissues, and review several examples of the clinical use of CD44v6-specific antibodies. In nonmalignant tissues, CD44v6 expression is essentially restricted to a subset of epithelia. Intense and homogeneous expression of CD44v6 was reported for the majority of squamous cell carcinomas and a proportion of adenocarcinomas of differing origin, but was rarely seen in nonepithelial tumours. This expression pattern has made CD44v6 an attractive target for antibody-guided therapy of various types of epithelium-derived cancers.

PMID:
14762695
DOI:
10.1007/s00262-003-0494-4
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center